P8A:SGX
Cordlife Group Ltd
SGD 0.12
0.00%
(0.00) 1D
10월 12일, 오전 9시 49분 20초 GMT+8 · SGD
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoP8A의 주요 통계 생성 중...
시가총액
3237.06만
평균 거래량
1.32천
거래량
0.00
52주 최고가
SGD 0.26
52주 최저가
SGD 0.10
EPS
-SGD 0.04
유통 주식수
2.68억
직원 수
111
시가총액
3237.06만
평균 거래량
1.32천
거래량
0.00
52주 최고가
SGD 0.26
52주 최저가
SGD 0.10
EPS
-SGD 0.04
유통 주식수
2.68억
직원 수
111
뉴스 기사
웹 소스 및 뉴스 파트너 제공
CBC뉴스
·
52분 전
미국 증시 16일 혼조세…다우 350포인트 상승, 나스닥은 0.73% 하락
Benzinga
·
31분 전
코베이시 레터 “이란 전쟁 없었다면 S&P 500 9,000p 가능”
연합인포맥스
·
10시간 전
'스페이스X로 대박'…하버드대 기금 수익률, S&P 500지수보다 높은 27%
프로필
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Cordlife Group Ltd에 관한 정보